EDIT · NASDAQ · Biotechnology

Editas Medicine (EDIT)

Develops an in vivo CRISPR candidate for lowering LDL cholesterol.

$2.84
vs last close−0.08 (−2.80%)
  1. Is Editas Medicine Going to $0?

    The Motley Fool